Frazier Healthcare Partners, a life sciences focused venture capital firm, closed Frazier Life Sciences X, L.P., at more than $617m.
Frazier Life Sciences X marks the third dedicated Life Sciences fund of the firm, bringing total committed capital raised since inception to nearly $4.8 billion.
Led by General Partners Patrick Heron, James Topper and Dan Estes, the Frazier Life Sciences team invests primarily in therapeutics-focused companies developing and commercializing innovative biopharmaceuticals that address important unmet medical needs.
Frazier Life Sciences X will continue its strategy of investing in company creation, early-stage venture and late private/public opportunities, with two-thirds of its investments expected to be in Seed and Series A rounds.
Founded in 1991, Frazier Healthcare Partners is a provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Recent Frazier Life Sciences IPOs and exits include Acerta (acquired by AstraZeneca), Mirum Pharmaceuticals (NASDAQ: MIRM), and Ignyta (acquired by Roche), as well as Frazier-founded companies Mavupharma (acquired by AbbVie), Phathom Pharmaceuticals (IPO: PHAT), and Silvergate Pharmaceuticals (acquired by CutisPharma).
The team has created or seeded 23 companies since 2005.
The firm has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada and Europe.